| Assessing the impact of law enforcement to reduce over-the-counter (OTC) sales of antibiotics in low-and middle-income countries; a systematic literature review TG Jacobs, J Robertson, HA van den Ham, K Iwamoto, H Bak Pedersen, ... BMC health services research 19, 1-15, 2019 | 113 | 2019 |
| Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review TG Jacobs, EM Svensson, V Musiime, P Rojo, KE Dooley, H McIlleron, ... Journal of Antimicrobial Chemotherapy 75 (12), 3433-3457, 2020 | 28 | 2020 |
| The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study TG Jacobs, H Hilda Ampadu, J Hoekman, ANO Dodoo, ... BMC Public Health 18, 1-11, 2018 | 22 | 2018 |
| Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial P Amuge, A Lugemwa, B Wynne, HA Mujuru, A Violari, CM Kityo, ... The Lancet HIV 9 (9), e638-e648, 2022 | 12 | 2022 |
| Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority … A Turkova, H Waalewijn, MK Chan, PDJ Bollen, ... The Lancet HIV 9 (9), e627-e637, 2022 | 11 | 2022 |
| What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studies TG Jacobs, S Schouwenburg, M Penazzato, M Archary, TD Ruel, ... The Lancet HIV 9 (9), e649-e657, 2022 | 9 | 2022 |
| Dexamethasone is a dose-dependent perpetrator of drug–drug interactions: implications for use in people living with HIV TG Jacobs, C Marzolini, DJ Back, DM Burger Journal of Antimicrobial Chemotherapy 77 (3), 568-573, 2022 | 7 | 2022 |
| Raltegravir-based postnatal HIV prophylaxis therapy in a neonate after in utero dolutegravir exposure TG Jacobs, KJ van Aerde, A Colbers, DM Burger The Pediatric Infectious Disease Journal 41 (2), 131-132, 2022 | 4 | 2022 |
| Model-informed intermittent tenofovir disoproxil fumarate and emtricitabine dosing for HIV pre-exposure prophylaxis in subjects with renal impairment: A case report L Zino, TG Jacobs, T Nieuwenstein, K Grintjes, A Colbers, DM Burger Aids 37 (2), 363-365, 2023 | 2 | 2023 |
| Lamivudine and emtricitabine dosing proposal for children with HIV and chronic kidney disease, supported by physiologically based pharmacokinetic modelling TG Jacobs, MA de Hoop-Sommen, T Nieuwenstein, JEM van der Heijden, ... Pharmaceutics 15 (5), 1424, 2023 | 1 | 2023 |
| Brief report: suboptimal lopinavir exposure in infants on rifampicin treatment receiving double-dosed or semisuperboosted lopinavir/ritonavir: time for a change TG Jacobs, V Mumbiro, M Chitsamatanga, N Namuziya, A Passanduca, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 93 (1), 42-46, 2023 | 1 | 2023 |
| Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report MAA van der Veer, TG Jacobs, LH Bukkems, APH Colbers, DM Burger, ... Antiviral therapy 27 (4), 13596535221119932, 2022 | 1 | 2022 |
| Ritonavir-boosted antiretroviral therapy with paclitaxel: will it lead to boosted toxicity? IG Murdoch, TG Jacobs, RM Nieuwenhuize, QC van Rossum-Schornagel, ... AIDS 36 (2), 322-323, 2022 | 1 | 2022 |
| Use of WHO paediatric weight-band dosing in drug labels TG Jacobs, H Waalewijn, A Colbers The Lancet HIV 9 (1), e3-e4, 2022 | 1 | 2022 |
| Carbamazepine intervention in a patient with efavirenz-induced liver injury TG Jacobs, DM Burger, AD Pranger, SH Khoo, JPH Drenth, R van Crevel Aids 33 (6), 1097-1098, 2019 | 1 | 2019 |
| Availability and stock‐outs of paediatric antiretroviral treatment formulations at health facilities in Kenya and Uganda TG Jacobs, D Okemo, A Ssebagereka, K Mwehonge, EM Njuguna, ... HIV medicine, 2024 | | 2024 |
| Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL Trial TG Jacobs, V Mumbiro, U Cassia, K Zimba, D Nalwanga, A Ballesteros, ... Clinical Infectious Diseases 78 (3), 702-710, 2024 | | 2024 |
| First-line antituberculosis drug concentrations in infants with HIV and a history of recent admission with severe pneumonia C Chabala, TG Jacobs, C Moraleda, JM Ndaferankhande, V Mumbiro, ... Journal of the Pediatric Infectious Diseases Society 12 (11), 581-585, 2023 | | 2023 |
| What the Product Label Does Not Tell You About Drug–Drug Interaction Management: Time for a Re‐Appraisal DM Burger, M le Comte, EJ Smolders, TG Jacobs, R Ter Heine, ... The Journal of Clinical Pharmacology 63 (11), 1181-1185, 2023 | | 2023 |
| Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis … A Turkova, E White, AR Kekitiinwa, V Mumbiro, E Kaudha, A Liberty, ... The Lancet Child & Adolescent Health 7 (10), 718-727, 2023 | | 2023 |
